Atea Pharmaceuticals IncAVIR
Price$5.21

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$165.3MTTM through 30 Jun 2026
Free Cash Flow -$152.1MTTM through 30 Jun 2026

Margins

Current

Returns

-57.5%ROE
-50.2%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio7.82x
Net Debt-$301.8Mnet cash position
Cash & Equivalents$76.5M

Quality Metrics

Altman Z-Score1.63
Piotroski F-Score3 / 9
Earnings-Beat Rate0.0%

Multi-Year Trend

Revenue
'20'21
FY2021: $351.4M
Diluted EPS-$2.08TTM
'19'20'21'22'23'24'25
FY2025: $-1.94

Dividend

No dividend

Capital Allocation

R&D Spend$155.4M

Segment Performance

SegmentRevenueYoYOutlook
Antiviral Therapeutics$0
View details

Topline results from North American C-BEYOND trial expected mid-2026 and C-FORWARD trial outside North America anticipated year-end 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.